China joins with Philips for biomarker/Dx tests research:
This article was originally published in Clinica
China's Institute of Health Sciences (IHS) and Royal Philips Electronics signed a memorandum of understanding on August 29 to establish a joint molecular medicine research laboratory. The lab, which will be located at the IHS in Shanghai, will focus on biomarker discovery and the development of next-generation in vitro diagnostic tests, with the aim of developing new solutions for the early diagnosis of disease and for monitoring the effectiveness of subsequent treatment. The IHS is part of the Shanghai Institutes for Biological Sciences (SIBS).
You may also be interested in...
FDA action awaits Sun’s manufacturing facility in Halol after it failed to adequately address GMP deviations, though India’s top-ranked drug firm appears to have effectively lowered its dependence on the site that has had a patchy compliance run.
In a surprise to the market, Dr Reddy’s and Hikma have prevailed in challenging six method-of-use patents shielding Amarin’s Vascepa in the US, opening the door for a potential at-risk launch that would likely be challenged by the originator.
Duo will study up to four novel preclinical targets identified by Sitryx that may lead to potential new drugs for autoimmune diseases, which Lilly would then commercialize.